The study surveyed SSMR members on chaperone use during genitourinary exams, revealing only one-third use them. Significant variability exists in chaperone policies, including patient choice and who ...

Talazoparib in the TALAPRO-1 trial improved progression-free survival and overall response rates in metastatic prostate cancer with specific genetic alterations. Rucaparib in the TRITON3 trial showed ...

Neal Shore, MD, FACS, highlights the exciting advancements in radioligand therapy for prostate cancer, noting that ongoing trials are exploring its use in various disease stages and settings, and ...

Significant disparities in testosterone supplementation usage exist among racial and insurance status groups, with African American and uninsured men under 40 being prominent users. Many young men ...

Vaginal estrogen for GSM shows no significant association with MACE, supporting its safety even in high-risk women. Systemic estrogen for VMS does not significantly increase VTE risk, indicating its ...

Nonsurgical BPH treatments require daily use and are not intended for long-term durability, appealing to patients preferring temporary solutions. Patient characteristics, such as kidney health and ...

The study investigates the link between testosterone replacement therapy, atrial fibrillation, and acute kidney injury. TriNetX, a global federated database, supports the study with data from over 109 ...

Long-term outcomes of Peyronie's surgery include significant penile length loss and erectile dysfunction, with 85% reporting length loss up to two years post-surgery. Surgical techniques impact ...

The PEACE III trial showed that BPAs reduced skeletal fracture risk from 33% to 3% in patients receiving radium-223. The radium-223 triplet regimen is considered superior to the enzalutamide doublet ...

Panelists discuss how the prevalence of metastatic castration-sensitive prostate cancer (mCSPC) has been increasing, potentially influenced by changes in prostate-specific antigen screening ...

Tailoring communication to patient preferences strengthens relationships and encourages loyalty in a concierge practice. HIPAA-compliant portals are recommended for healthcare information, while ...

UGN-102 showed a 79.6% complete response rate at 3 months in the ENVISION trial for LG-IR-NMIBC. The 12-month duration of response was 82.3%, with disease-free survival at 15 months reaching 76%. The ...